AR003919A1 - Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha - Google Patents

Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha

Info

Publication number
AR003919A1
AR003919A1 ARP960101095A AR10109596A AR003919A1 AR 003919 A1 AR003919 A1 AR 003919A1 AR P960101095 A ARP960101095 A AR P960101095A AR 10109596 A AR10109596 A AR 10109596A AR 003919 A1 AR003919 A1 AR 003919A1
Authority
AR
Argentina
Prior art keywords
protein
accessory protein
human
interleukin
antibody
Prior art date
Application number
ARP960101095A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR003919A1 publication Critical patent/AR003919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP960101095A 1995-01-23 1996-01-19 Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha AR003919A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
AR003919A1 true AR003919A1 (es) 1998-09-30

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101095A AR003919A1 (es) 1995-01-23 1996-01-19 Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha

Country Status (19)

Country Link
EP (1) EP0808365A1 (ru)
JP (1) JPH10512453A (ru)
AR (1) AR003919A1 (ru)
AU (1) AU4537096A (ru)
BR (1) BR9606837A (ru)
CA (1) CA2210724A1 (ru)
CO (1) CO4480033A1 (ru)
CZ (1) CZ208197A3 (ru)
EA (1) EA199700265A1 (ru)
FI (1) FI973089A0 (ru)
HU (1) HUP9702458A2 (ru)
IL (1) IL116796A0 (ru)
MX (1) MX9705501A (ru)
NO (1) NO973404D0 (ru)
PE (1) PE64396A1 (ru)
PL (1) PL321538A1 (ru)
TR (1) TR199700652T1 (ru)
WO (1) WO1996023067A1 (ru)
ZA (1) ZA96333B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
CA2316034A1 (en) 1997-12-23 1999-07-01 Immunex Corporation Sigirr dna and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2002253842A1 (en) 2000-10-31 2002-08-28 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
DK1572946T3 (da) 2002-09-06 2012-07-02 Amgen Inc Terapeutisk humant monoklonalt anti-IL-1R1-antistof
CA2557910C (en) 2004-04-02 2012-05-29 Amgen Inc. Methods of reducing aggregation of il-1ra
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1751175B1 (en) * 2004-05-05 2012-07-25 VALORISATION-RECHERCHE, Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US20110044894A1 (en) 2008-03-26 2011-02-24 Cellerant Therapeutics, Inc. Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
KR101989134B1 (ko) * 2011-01-19 2019-06-13 칸타르기아 아베 항―ｉｌ１ｒａｐ 항체 및 그의 인간 치료 용도
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
CA2837651A1 (en) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP4428863A2 (en) 2015-05-11 2024-09-11 Natera, Inc. Methods and compositions for determining ploidy
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3781714A1 (en) 2018-04-14 2021-02-24 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
CN114835799A (zh) * 2021-05-28 2022-08-02 百奥赛图江苏基因生物技术有限公司 Il1rap基因人源化非人动物的构建方法及应用
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Also Published As

Publication number Publication date
NO973404L (no) 1997-07-23
ZA96333B (en) 1996-07-23
AU4537096A (en) 1996-08-14
NO973404D0 (no) 1997-07-23
MX9705501A (es) 1997-10-31
EA199700265A1 (ru) 1998-04-30
PL321538A1 (en) 1997-12-08
EP0808365A1 (en) 1997-11-26
JPH10512453A (ja) 1998-12-02
CA2210724A1 (en) 1996-08-01
IL116796A0 (en) 1996-05-14
WO1996023067A1 (en) 1996-08-01
BR9606837A (pt) 1998-05-26
HUP9702458A2 (hu) 1998-04-28
CO4480033A1 (es) 1997-07-09
CZ208197A3 (en) 1997-11-12
FI973089A (fi) 1997-07-22
FI973089A0 (fi) 1997-07-22
TR199700652T1 (xx) 1998-02-21
PE64396A1 (es) 1997-01-28

Similar Documents

Publication Publication Date Title
AR003919A1 (es) Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha
Vitaliano et al. The relative importance of risk factors in nonmelanoma carcinoma
Rosenthal et al. Seasonal affective disorders
Karagülle et al. Effect of spa therapy with saline balneotherapy on oxidant/antioxidant status in patients with rheumatoid arthritis: a single-blind randomized controlled trial
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
RU2010108429A (ru) Регуляторы ммр-9 и их применение
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
Abelaira et al. Ketamine exhibits different neuroanatomical profile after mammalian target of rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress
Bastos Moura et al. A novel model of megavoltage radiation-induced oral mucositis in hamsters: Role of inflammatory cytokines and nitric oxide
ES2166770T3 (es) Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
BRPI0311511A8 (pt) "preparações farmacêuticas líquidas, e sua aplicação".
Akmese et al. Differential role of GABAergic and cholinergic ventral pallidal neurons in behavioral despair, conditioned fear memory and active coping
O’Connor et al. Endurance exercise attenuates juvenile irradiation-induced skeletal muscle functional decline and mitochondrial stress
ES2144054T3 (es) Complejos de tri(platino).
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.
Dogra et al. Phototherapy and photochemotherapy in childhood dermatoses
Orjuela‐Grimm et al. Sunlight exposure in infancy decreases risk of sporadic retinoblastoma, extent of intraocular disease
Ghoreishi Heat shock proteins in the pathogenesis of inflammatory skin diseases
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
Baliño et al. Role of CA2+/calmodulin on ethanol neurobehavioral effects